VTVT News and Press, vTv Therapeutics Inc. From 02/07/20

Thinly traded micro cap vTv Therapeutics (NASDAQ: VTVT ) is up  21%  after hours in response to its announcement that it will release topline data from Part 2 of a Phase 2 clinical trial, Simplici-T1 , evaluating TTP399 as oral adjunctive therapy to insulin in adults with type 1...

HIGH POINT, N.C., Feb. 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced that it will release the topline results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

The following slide deck was published by vTv Therapeutics Inc. in conjunction with this Read more ...

Gainers: Cemtrex (NASDAQ: CETX )  +100% . More news on: Cemtrex, Inc., OrganiGram Holdings Inc., Fluent, Inc., Stocks on the move, , Read more ...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

VTv Therapeutics (NASDAQ: VTVT ) is up 7% after hours following a boost to the majority stake held by Ron Perelman's MacAndrews & Forbes. More news on: vTv Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...

Introduction Through Week 49, the Premium Portfolio has gained +27.75%, beating the S&P 500 benchmark, while actively trading in 14 fewer weeks according to the Momentum Gauge timing signals. These returns represent better than 3 times the return of the Barclay Hedge Fund Index average r...

HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and Alzheimer’s disease, today announced that it is scheduled to p...

vTv Therapeutics (NASDAQ: VTVT ): Q3 Non-GAAP EPS of -$0.10; GAAP EPS of -$0.13 misses by $0.07 . More news on: vTv Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...